Potential of miR-181a-5p and miR-630 as clinical biomarkers in NSCLC

202317 citationsJournal Articlegold Open Access

Authors

Julija Šimienė · National Cancer Institute

Daiva Dabkevičienė · National Cancer Institute

Diana Stančiūtė · National Cancer Institute

Rimvilė Prokarenkaitė · Vilnius University

Valerija Jablonskienė · Vilnius University

Renatas Aškinis · National Cancer Institute

Kamile Normantaite

Abstract

Our findings indicate the miR-181a-5p and miR-630 expression levels have the potential to prognose and predict and therefore improve the treatment individualization and the outcome of NSCLC patients. Circulating miR-181a-5p has the potential clinical value as a non-invasive biomarker for NSCLC.

Topics & Keywords

MicroRNA in disease regulation Circular RNAs in diseases Cancer-related molecular mechanisms research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: BMC Cancer

Volume 23, Issue 1, pp. 857-857

DOI: 10.1186/s12885-023-11365-5

Field-Weighted Citation Impact: 4.11